Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function

A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function

Inclusion Criteria:

• Male or female aged 18 or above
• Congestive Heart Failure with symptoms for more than 4 weeks before starting study
• Provision of informed consent

Exclusion Criteria:

• Current low blood pressure with symptoms
• Liver disease considered significant by the study doctor
• Pregnant or lactating females